Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

Broeckelmann, Paul J.; Buehnen, Ina; Meissner, Julia; Trautmann-Grill, Karolin; Herhaus, Peter; Halbsguth, Teresa V.; Schaub, Valdete; Kerkhoff, Andrea; Mathas, Stephan; Bormann, Matthias; Dickhut, Andreas; Kaul, Helen; Fuchs, Michael; Kobe, Carsten; Baues, Christian; Borchmann, Peter; Engert, Andreas; von Tresckow, Bastian

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

Autor(en):

Broeckelmann, Paul J.; Buehnen, Ina; Meissner, Julia; Trautmann-Grill, Karolin; Herhaus, Peter; Halbsguth, Teresa V.; Schaub, Valdete; Kerkhoff, Andrea; Mathas, Stephan; Bormann, Matthias; Dickhut, Andreas; Kaul, Helen; Fuchs, Michael; Kobe, Carsten; Baues, Christian; Borchmann, Peter; Engert, Andreas; von Tresckow, Bastian

Tübinger Autor(en):

Schaub, Valdete

Erschienen in:

Journal of Clinical Oncology (2023), Bd. 41, H. 6, S. 1193

Verlagsangabe:

Lippincott Williams & Wilkins

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.22.02355

ISSN:

0732-183X